This report was recently updated on December 11 2024 with the latest and most recent
market numbers
Global Viral Vector Manufacturing Market Size, Trends & Analysis - Forecasts to 2027 By Type (Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Other Viral Vectors), By Disease (Cancers, Genetic Disorders, Infectious diseases, Other Diseases), By Application (Gene Therapy and Vaccinology), By End-User (Pharmaceutical and Bio-pharmaceutical Companies, and Research Institutes), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa), Company Market Share Analysis, and Competitor Analysis
The global viral vector manufacturing market is projected to grow at a CAGR value of 20.5% from 2022 to 2027.
Viral vectors are being considered as potential regenerative medicine and vaccine technologies and the capacity of these viruses to infect cells is the basis for their usefulness. In general, viral vectors offer the following advantages such as high-efficiency gene transmission, highly specific targeted therapy to treat cancer, generation of powerful immune responses, and improved cellular immunity.
Recombinant viral vectors have therapeutic potential since they allow intracellular antigen interpretation and stimulate a rigorous cytotoxic T lymphocyte (CTL) reaction, leading to the elimination of virus-infected molecules that are driving the market growth. Additionally, other benefits of viral vectors include enhanced safety and effectiveness, lowered administration dosing frequency, large-scale industrial production, and possible targets ranging from cancer to a wide variety of infectious diseases are also propelling the market growth during the forecast period.
The rise in a variety of genetic abnormalities and contagious diseases is influencing viral vector generation as well. In particular, as per the Joint United Nations Programme on HIV/AIDS (UNAIDS) Data, at the end of 2020, 27.5 million people worldwide were living with HIV, and 1.5 million individuals became newly infected. Furthermore, government initiatives such as direct funding for viral vector manufacturing, rising demand for innovative clinical therapies, and a growing focus on the emerging area of medicine, which is aided by transforming techniques, are driving market expansion.
The rising number of cancer patients affected by increased alcohol intake and unhealthy lifestyles, as well as the burgeoning utilization of viral vectors in novel therapeutic delivery, along with their use as effective carriers of virus-disabling sequence data and their convenience in delivering HIV-inhibiting transgenic organisms to human hematopoietic stem cells (HSCs), are all making a significant contribution to market expansion.
Nevertheless, the possibility of incorporating into the host chromosome and causing additional diseases, the existence of pre-existing resistance against the vector as a result of past virus infection, and the creation of neutralizing antibodies, which can diminish vaccination efficacy, are all stifling market expansion.
The pandemic of COVID-19 has highlighted the need for vaccine development for the global population, and it has boosted the viral vector manufacturing market. As per the World Health Organization (WHO), at least 17 vaccinations are now in use, with 5.4 billion doses delivered as of September 6, 2021, and another 300 vaccine candidates in pre-clinical and clinical testing. Due to the sheer current state of research and innovation, viral vector production is becoming increasingly important.
Based on the type, the global viral vector manufacturing market is fragmented into retroviral vectors, adenoviral vectors, adeno-associated viral vectors, other viral vectors. The adeno-associated viral vector segment is expected to grow the fastest in the viral vector manufacturing market from 2022 to 2027. Vaccinia virus and adenovirus are the most extensively utilized vectors since they may elicit an effective immune response against expressed foreign substances, specifically involving CTL.
In most cases, viral vectors acquire high responsiveness without the addition of an adjuvant. The inflammatory response is stimulated by viral components, which results in the formation of interferons and cytokine production.
The viral vector manufacturing market is divided into cancers, genetic disorders, infectious diseases, and other diseases based on the disease. The cancers segment is expected to grow the fastest in the viral vector manufacturing market from 2022 to 2027. The increase in popularity for the creation of efficient therapeutics for cancer management, the presence of a quick review and approval, and the opportunities for novel drugs for significant product developments are the primary reasons for extensive research and development investment opportunities in the field of cancer therapeutics based on viral vectors. This positively affects the cancer segment's growth during the forecast period.
Based on the application, the viral vector manufacturing market is divided into gene therapy and vaccinology. The gene therapy segment is expected to hold a larger share as compared to other segments. Integration into the host chromosome, no viral genetics, ability to genetically engineer cells that are not actively proliferating, wide variety of host cells, and non-inflammatory and non-pathogenic are all advantages of employing viral virus as the vector in gene therapy experiments.
Based on the end-user, the viral vector manufacturing market is divided into pharmaceutical and biopharmaceutical companies, and research institutes. The pharmaceutical and biopharmaceutical segment is expected to grow the fastest in the viral vector manufacturing market from 2022 to 2027. The expansion of this market is being driven by an increase in pharmaceutical and biopharmaceutical businesses, a rise in the number of CROs, and an expansion in R&D expenditure.
As per the geographical analysis, the viral vector manufacturing market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central & South America (Brazil, Argentina, and Rest of Central and South America).
North America (the United States, Canada, and Mexico), will have a dominant share in the viral vector manufacturing market from 2022 to 2027. The rise in the prevalence of genetic and other chronic illnesses, the surging aging population, the rising demand for targeted and customized medication, and supportive government initiatives are all driving future market expansion in the US.
Moreover, the Asia Pacific (India, China, Japan, Malaysia, Singapore, and the Rest of Asia Pacific) region is expected to be the fastest-growing segment in the viral vector vaccine market during the forecast period. The market would be propelled by the growing geriatric population, the rising incidence of chronic diseases, rising healthcare expenditures, and expanding consumer purchasing power. Also, increased R&D expenditures by market participants, as well as greater government investment in vaccine development, are all contributing to market expansion in this region.
Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, uniQure, FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Johnson & Johnson (Janssen Global Services, LLC, Vibalogics, among others are key players in the viral vector manufacturing market.
Please note: This is not an exhaustive list of companies profiled in the report.
Report Content
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Viral Vector Manufacturing Industry Overview, 2022-2027
2.1.1 Industry Overview
2.1.2 Type Overview
2.1.3 Diseases Overview
2.1.4 Application Overview
2.1.5 End User Overview
2.1.6 Regional Overview
Chapter 3 Viral Vector Manufacturing Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2022-2027
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1. Rise in a variety of genetic abnormalities and contagious diseases
3.3.2 Industry Challenges
3.3.2.1 The possibility of incorporating into the host chromosome and causing additional diseases
3.4 Prospective Growth Scenario
3.4.1 Type Growth Scenario
3.4.2 Diseases Growth Scenario
3.4.3 Application Growth Scenario
3.4.4 End User Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 End User Overview
3.11 Market Share Analysis, 2021
3.11.1 Company Positioning Overview, 2021
Chapter 4 Viral Vector Manufacturing Market, By Type
4.1 Type Outlook
4.2 Retroviral Vectors
4.2.1 Market Size, By Region, 2022-2027 (USD Billion)
4.3 Adenoviral Vectors
4.3.1 Market Size, By Region, 2022-2027 (USD Billion)
4.4 Adeno-associated Viral Vectors
4.4.1 Market Size, By Region, 2022-2027 (USD Billion)
4.5 Other Viral Vectors
4.5.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 5 Viral Vector Manufacturing Market, By Application
5.1 Industry Outlook
5.2 Gene Therapy
5.2.1 Market Size, By Region, 2022-2027 (USD Billion)
5.3 Vaccinology
5.3.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 6 Viral Vector Manufacturing Market, By Diseases
6.1 Cancers
6.1.1 Market Size, By Region, 2022-2027 (USD Billion)
6.2 Genetic Disorders
6.2.1 Market Size, By Region, 2022-2027 (USD Billion)
6.3 Infectious diseases
6.3.1 Market Size, By Region, 2022-2027 (USD Billion)
6.4 Other Diseases
6.4.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 7 Viral Vector Manufacturing Market, By End User
7.1 Pharmaceutical and Bio-pharmaceutical Companies
7.1.1 Market Size, By Region, 2022-2027 (USD Billion)
7.2 Research Institutes
7.2.1 Market Size, By Region, 2022-2027 (USD Billion)
Chapter 8 Viral Vector Manufacturing Market, By Region
8.1 Regional outlook
8.2 North America
8.2.1 Market Size, By Country 2022-2027 (USD Billion)
8.2.2 Market Size, By Type, 2022-2027 (USD Billion)
8.2.3 Market Size, By Diseases, 2022-2027 (USD Billion)
8.2.4 Market Size, By Application, 2022-2027 (USD Billion)
8.2.5 Market Size, By End User, 2022-2027 (USD Billion)
8.2.6 U.S.
8.2.6.1 Market Size, By Type, 2022-2027 (USD Billion)
8.2.4.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.2.4.3 Market Size, By Application, 2022-2027 (USD Billion)
Market Size, By End User, 2022-2027 (USD Billion)
8.2.7 Canada
8.2.7.1 Market Size, By Type, 2022-2027 (USD Billion)
8.2.7.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.2.7.3 Market Size, By Application, 2022-2027 (USD Billion)
8.2.7.4 Market Size, By End User, 2022-2027 (USD Billion)
8.3 Europe
8.3.1 Market Size, By Country 2022-2027 (USD Billion)
8.3.2 Market Size, By Type, 2022-2027 (USD Billion)
8.3.3 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.4 Market Size, By Application, 2022-2027 (USD Billion)
8.3.5 Market Size, By End User, 2022-2027 (USD Billion)
8.3.6 Germany
8.3.6.1 Market Size, By Type, 2022-2027 (USD Billion)
8.3.6.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.6.3 Market Size, By Application, 2022-2027 (USD Billion)
8.3.6.4 Market Size, By End User, 2022-2027 (USD Billion)
8.3.7 UK
8.3.7.1 Market Size, By Type, 2022-2027 (USD Billion)
8.3.7.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.7.3 Market Size, By Application, 2022-2027 (USD Billion)
8.3.7.4 Market Size, By End User, 2022-2027 (USD Billion)
8.3.8 France
8.3.8.1 Market Size, By Type, 2022-2027 (USD Billion)
8.3.8.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.8.3 Market Size, By Application, 2022-2027 (USD Billion)
8.3.8.4 Market Size, By End User, 2022-2027 (USD Billion)
8.3.9 Italy
8.3.9.1 Market Size, By Type, 2022-2027 (USD Billion)
8.3.9.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.9.3 Market Size, By Application, 2022-2027 (USD Billion)
8.3.9.4 Market Size, By End User, 2022-2027 (USD Billion)
8.3.10 Spain
8.3.10.1 Market Size, By Type, 2022-2027 (USD Billion)
8.3.10.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.10.3 Market Size, By Application, 2022-2027 (USD Billion)
8.3.10.4 Market Size, By End User, 2022-2027 (USD Billion)
8.3.11 Russia
8.3.11.1 Market Size, By Type, 2022-2027 (USD Billion)
8.3.11.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.3.11.3 Market Size, By Application, 2022-2027 (USD Billion)
8.3.11.4 Market Size, By End User, 2022-2027 (USD Billion)
8.4 Asia Pacific
8.4.1 Market Size, By Country 2022-2027 (USD Billion)
8.4.2 Market Size, By Type, 2022-2027 (USD Billion)
8.4.3 Market Size, By Diseases, 2022-2027 (USD Billion)
8.4.4 Market Size, By Application, 2022-2027 (USD Billion)
8.4.5 Market Size, By End User, 2022-2027 (USD Billion)
8.4.6 China
8.4.6.1 Market Size, By Type, 2022-2027 (USD Billion)
8.4.6.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.4.6.3 Market Size, By Application, 2022-2027 (USD Billion)
8.4.6.4 Market Size, By End User, 2022-2027 (USD Billion)
8.4.7 India
8.4.7.1 Market Size, By Type, 2022-2027 (USD Billion)
8.4.7.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.4.7.3 Market Size, By Application, 2022-2027 (USD Billion)
8.4.7.4 Market Size, By End User, 2022-2027 (USD Billion)
8.4.8 Japan
8.4.8.1 Market Size, By Type, 2022-2027 (USD Billion)
8.4.8.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.4.8.3 Market Size, By Application, 2022-2027 (USD Billion)
8.4.8.4 Market Size, By End User, 2022-2027 (USD Billion)
8.4.9 Australia
8.4.9.1 Market Size, By Type, 2022-2027 (USD Billion)
8.4.9.2 Market size, By Diseases, 2022-2027 (USD Billion)
8.4.9.3 Market Size, By Application, 2022-2027 (USD Billion)
8.4.9.4 Market Size, By End User, 2022-2027 (USD Billion)
8.4.10 South Korea
8.4.10.1 Market Size, By Type, 2022-2027 (USD Billion)
8.4.10.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.4.10.3 Market Size, By Application, 2022-2027 (USD Billion)
8.4.10.4 Market Size, By End User, 2022-2027 (USD Billion)
8.5 Latin America
8.5.1 Market Size, By Country 2022-2027 (USD Billion)
8.5.2 Market Size, By Type, 2022-2027 (USD Billion)
8.5.3 Market Size, By Diseases, 2022-2027 (USD Billion)
8.5.4 Market Size, By Application, 2022-2027 (USD Billion)
8.5.5 Market Size, By End User, 2022-2027 (USD Billion)
8.5.6 Brazil
8.5.6.1 Market Size, By Type, 2022-2027 (USD Billion)
8.5.6.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.5.6.3 Market Size, By Application, 2022-2027 (USD Billion)
8.5.6.4 Market Size, By End User, 2022-2027 (USD Billion)
8.5.7 Mexico
8.5.7.1 Market Size, By Type, 2022-2027 (USD Billion)
8.5.7.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.5.7.3 Market Size, By Application, 2022-2027 (USD Billion)
8.5.7.4 Market Size, By End User, 2022-2027 (USD Billion)
8.5.8 Argentina
8.5.8.1 Market Size, By Type, 2022-2027 (USD Billion)
8.5.8.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.5.8.3 Market Size, By Application, 2022-2027 (USD Billion)
8.5.8.4 Market Size, By End User, 2022-2027 (USD Billion)
8.6 MEA
8.6.1 Market Size, By Country 2022-2027 (USD Billion)
8.6.2 Market Size, By Type, 2022-2027 (USD Billion)
8.6.3 Market Size, By Diseases, 2022-2027 (USD Billion)
8.6.4 Market Size, By Application, 2022-2027 (USD Billion)
8.6.5 Market Size, By End User, 2022-2027 (USD Billion)
8.6.6 Saudi Arabia
8.6.6.1 Market Size, By Type, 2022-2027 (USD Billion)
8.6.6.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.6.6.3 Market Size, By Application, 2022-2027 (USD Billion)
8.6.6.4 Market Size, By End User, 2022-2027 (USD Billion)
8.6.7 UAE
8.6.7.1 Market Size, By Type, 2022-2027 (USD Billion)
8.6.7.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.6.7.3 Market Size, By Application, 2022-2027 (USD Billion)
8.6.7.4 Market Size, By End User, 2022-2027 (USD Billion)
8.6.8 South Africa
8.6.8.1 Market Size, By Type, 2022-2027 (USD Billion)
8.6.8.2 Market Size, By Diseases, 2022-2027 (USD Billion)
8.6.8.3 Market Size, By Application, 2022-2027 (USD Billion)
8.6.8.4 Market Size, By End User, 2022-2027 (USD Billion)
Chapter 9 Company Landscape
9.1 Competitive Analysis, 2020
9.2 Lonza
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Strategic Positioning
9.2.4 Info Graphic Analysis
9.3 Merck
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Strategic Positioning
9.3.4 Info Graphic Analysis
9.4 Oxford BioMedica
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Strategic Positioning
9.4.4 Info Graphic Analysis
9.5 CGT Catapult
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Strategic Positioning
9.5.4 Info Graphic Analysis
9.6 Cobra Biologics
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Strategic Positioning
9.6.4 Info Graphic Analysis
9.7 uniQure
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Strategic Positioning
9.7.4 Info Graphic Analysis
9.8 FUJIFILM Diosynth Biotechnologies
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Strategic Positioning
9.8.4 Info Graphic Analysis
9.9 Spark Therapeutics
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Strategic Positioning
9.9.4 Info Graphic Analysis
9.10 AstraZeneca
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Strategic Positioning
9.10.4 Info Graphic Analysis
9.11 Other Companies
9.11.1 Company Overview
9.11.2 Financial Analysis
9.11.3 Strategic Positioning
9.11.4 Info Graphic Analysis
The Global Viral Vector Manufacturing Market has been studied from the year 2019 till 2027. However, the CAGR provided in the report is from the year 2022 to 2027. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Viral Vector Manufacturing Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
